Loading...

Oncolytics Biotech Inc.

ONC.TO•TSX
Healthcare
Biotechnology
CA$0.87
CA$0.05(6.10%)

Oncolytics Biotech Inc. (ONC.TO) Stock Overview

Explore Oncolytics Biotech Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
CA$-0.41
EPS Growth
CA$-0.41
Operating Margin
0.00%
ROE
-225.21%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ONC.TOAnalyst Recommendations details for ONC.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

CEO

Mr. Wayne F. Pisano M.B.A.

Employees

28

Headquarters

322 11th Avenue SW, Calgary, AB

Founded

2000

Frequently Asked Questions